Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Natera Inc    NTRA

NATERA INC (NTRA)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/10/2018 01/11/2018 01/12/2018 01/16/2018 01/17/2018 Date
9.71(c) 10.1(c) 10.18(c) 9.87(c) 10.21(c) Last
60 518 110 571 97 954 93 899 146 590 Volume
-0.61% +4.02% +0.79% -3.05% +3.44% Change
More quotes
Financials ($)
Sales 2017 217 M
EBIT 2017 -113 M
Net income 2017 -117 M
Finance 2017 14,3 M
Yield 2017 -
Sales 2018 265 M
EBIT 2018 -75,6 M
Net income 2018 -89,4 M
Debt 2018 24,6 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 2,46x
EV / Sales2018 2,17x
Capitalization 549 M
More Financials
Company
Natera, Inc. engages in the discovery, development, and commercialization of genetic testing services.It offers Panorama Non-Invasive Prenatal Test; Horizon Carrier Screening; Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis; Anora Products of Conception;... 
More about the company
Surperformance© ratings of Natera Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on NATERA INC
01/08 NATERA : To Webcast Live Presentation at the 36th Annual J.P. Morgan Healthcare ..
2017 NATERA : Chosen for Circulating Tumor DNA Study in Breast Cancer
2017 NATERA : Selected for Circulating Tumor DNA Study in Colorectal Cancer
2017 NATERA : Chosen for Longitudinal Circulating Tumor DNA Study in Breast Cancer
2017 NATERA : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS..
2017 NATERA : reports 3Q loss
2017 NATERA, INC. : Results of Operations and Financial Condition, Financial Statemen..
2017 NATERA : Reports Third Quarter 2017 Financial Results
2017 NATERA INC : Natera, Inc. to Host Earnings Call
2017 NATERA : Chosen for Longitudinal Circulating Tumour DNA Study in Breast Cancer
More news
Sector news : Diagnostic & Testing Substances
01/12 China cracks down on foreign companies calling Taiwan, other regions countrie..
01/12 China cracks down on foreign companies calling Taiwan, other regions countrie..
01/12 Delta, Zara and Medtronic Join Marriott in Beijing's Doghouse After Location ..
01/08 MALLINCKRODT : to Sell Two Hemostasis Products to Baxter
01/07 BAXTER INTERNATIONAL : Hospitals Wrestle With Shortage of IV Bags, Linked to Hur..
More sector news : Diagnostic & Testing Substances
Latest Tweets
01/17RECAP 1/17 +Pos Comments: $FCX $SID $EAT $WATT $BUD $STM $YY -Neg Comments: $.. 
01/17On The Fly: Top five analyst initiations $DATA $AM $NTRA $DLR $PIRS  
01/12Want the latest analyst ratings on $QRE $FRF $NTRA $PFCB $CBU? Get Them Deliv.. 
01/08Natera To Webcast Live Presentation at the 36th Annual J.P. Morgan Healthcare.. 
2017Natera $NTRA Given “Buy” Rating at Cowen  
More tweets
Qtime:43
News from SeekingAlpha
01/12 Natera (NTRA) Presents At 36th Annual J.P. Morgan Healthcare Conference - Sli..
2017 Natera's (NTRA) CEO Matthew Rabinowitz on Q3 2017 Results - Earnings Call Tra..
2017 Natera 2017 Q3 - Results - Earnings Call Slides
2017 Natera misses by $0.03, beats on revenue
2017 Notable earnings after Wednesday?s close
Chart NATERA INC
Duration : Period :
Natera Inc Technical Analysis Chart | NTRA | US6323071042 | 4-Traders
Technical analysis trends NATERA INC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Average target price 15,5 $
Spread / Average Target 52%
EPS Revisions
Managers
NameTitle
Matthew Rabinowitz Chairman, President & Chief Executive Officer
Stephen Chapman Chief Operating Officer
Michael Brophy Chief Financial Officer
Jonathan Sheena Director & Chief Technology Officer
Cheng-Ho Lin Chief Scientific Officer-Oncology
Sector and Competitors
1st jan.Capitalization (M$)
NATERA INC9.79%531
BIOMERIEUX4.43%11 304
DIASORIN SPA7.23%5 436
AUTOBIO DIAGNOSTICS CO LTD-6.13%3 261
MACCURA BIOTECHNOLOGY CO LTD--.--%1 877
SIEGFRIED HOLDING AG0.15%1 419